Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Researchers have used deep learning to assess three key biomarkers of existing breast cancers on routinely acquired histology slides. In the process, the team has advanced AI-based biomarker analysis for managing a range of cancers.
When a black-box algorithm guides a physician’s diagnostic or therapeutic judgments, its intrinsic opaqueness can confound subsequent steps toward clinical safety and efficacy—and that’s just for starters.
An AI tool for managing pediatric asthma shaved 7.8 minutes from the time pediatricians spent dealing with electronic health records in a randomized clinical trial conducted at the Mayo Clinic.
Deep learning can accurately distinguish dementia from mild cognitive impairment by looking at pictures of analog clocks as drawn by individuals thought to be affected.
AI-aimed blasting of kidney stones from outside the body hit intended targets at a 75% clip in a proof-of-concept study, pulverizing conventional lithotripsy, which missed the mark almost half the time.
A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos.
Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025.
Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.
